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Hayley D. Ackerman and Glenn S. Gerhard*
Department of Medical Genetics and Molecular Biochemistry, The Lewis Katz School of Medicine at Temple University,
Philadelphia, PA, USA
Bile acids, a structurally related group of molecules derived from cholesterol, have a long
history as therapeutic agents in medicine, from treatment for primarily ocular diseases
in ancient Chinese medicine to modern day use as approved drugs for certain liver
diseases. Despite evidence supporting a neuroprotective role in a diverse spectrum of
age-related neurodegenerative disorders, including several small pilot clinical trials, little
is known about their molecular mechanisms or their physiological roles in the nervous
system. We review the data reported for their use as treatments for neurodegenerative
diseases and their underlying molecular basis. While data from cellular and animal
models and clinical trials support potential efficacy to treat a variety of neurodegenerative
disorders, the relevant bile acids, their origin, and the precise molecular mechanism(s)
by which they confer neuroprotection are not known delaying translation to the clinical
setting.
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BACKGROUND
Bile acids are a structurally related group of molecules derived from cholesterol that are widely
known for their role as chemical detergents involved in the intestinal absorption and transport
of fats and lipid-soluble nutrients (Schonewille et al., 2016). However, bile acids also appear to
play as yet poorly defined physiological roles in the central nervous system (Lieu et al., 2014).
Surprisingly little work has been done on the physiological roles of bile acids in neurons or
the central nervous system (Zhang et al., 1997) despite a wide array of data in model systems
and despite the significant therapeutic advantages of bile acids. Bile acids are readily bioavailable
via oral, subcutaneous, or intravenous administration, can cross the blood-brain barrier, are
relatively nontoxic, and have been approved by the U.S. Food and Drug Administration for human
therapeutic use. We review evidence supporting a potentially therapeutic role for bile acids in a
number of diverse neurodegenerative conditions. A summary of the studies described below is
presented in Tables 1, 2.
BIOLOGY OF BILE ACIDS
Two aspects of bile acid metabolism are relevant to their role in neurodegenerative disorders,
bile acids that circulate systemically and that are synthesized by neurons. Circulating bile acids
are largely synthesized from cholesterol in the liver (Prawitt et al., 2011). Ingestion of food causes
bile acid secretion from the gallbladder through the common bile duct to the duodenum in order
to facilitate the absorption of lipids and lipid-soluble vitamins via formation of micelles. Upon
reaching the ileum, bile acids are transported by specific transport proteins to the portal circulation
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for recycling back to the liver. The process is highly efficient with
over 95% of bile acids resorbed, the remaining 5% proceeding to
the colon and excreted through the stool. Enterohepatic recycling
of the bile acid pool occurs about 12 times per day, thus the
net flux of bile acids through primarily the portal, but also the
systemic, circulation is substantial.
The two primary bile acids produced by the liver in humans
are cholic acid (CA) and chenodeoxycholic acid (CDCA). These
primary bile acids can undergo conjugation with glycine or
taurine prior to secretion in the bile to form glycocholic acid
(GCA), taurocholic acid (TCA), glycochenodeoxycholic acid
(GCDCA), and taurochenodeoxycholic acid (TCDCA). In the
intestine, they can undergo dehydroxylation by gut bacteria to
produce deoxycholic acid (DCA) and lithocholic acid (LCA).
Further chemical modifications can also occur resulting in other
minor species such as ursodeoxycholic acid (UDCA) (Zhang
et al., 1997).
Bile acids also function as signaling molecules through
interaction with several receptor systems (Figure 1). They serve
as ligands for the nuclear transcription factor farnesoid X
receptor (FXR), which forms a heterodimeric complex with
retinoid X receptor α (RXRα) that binds to an inverted repeat
sequence in gene promoters (Hoeke et al., 2014). They are
also agonists for a cellular receptor, the G protein-coupled bile
acid receptor 1 (GPBAR1 or TGR5), to mediate signaling via
the generation of cyclic adenosine monophosphate (cAMP) by
adenylate cyclase, which stimulates cAMP-dependent protein
kinase A (PKA) and phosphorylation of the cAMP response
element binding protein (CREB) transcription factor (Hodge and
Nunez, 2016; Schonewille et al., 2016).
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is characterized by dementia and
memory loss that is associated with extracellular senile plaques
of amyloid precursor protein derived amyloid-beta (Aβ) protein
and intracellular neurofibrillary tangles consisting of the Tau
protein (Scheltens et al., 2016). A primary in vitro model of
AD is therefore treatment of cells with Aβ peptide that causes
cytotoxicity to both primary cultures of neurons as well as
neuronal cell lines. Treatment of primary cortical neuron cultures
derived from Wistar rat embryos with tauroursodeoxycholic
acid (TUDCA) prior to exposure to Aβ peptide significantly
decreased nuclear fragmentation and cytochrome c release that
was dependent upon activation of the PI3K pathway (Solá et al.,
2003). The bile acid UDCA was found to regulate IκBα and NF-
κB regulated genes in the mechanism of protection against Aβ
toxicity in the BV-2 microglial cell line (Joo et al., 2004).
Certain steroid hormones exhibit neuroprotective properties
that are thought to be mediated in part through interaction
with nuclear steroid receptors, including the glucocorticoid,
and mineralocorticoid receptors (Garcia-Segura and Balthazart,
2009). Neurosteroids and bile acids are cholesterol derivatives
that share some structural similarity so certain bile acids are
natural ligands for these receptors. UDCA and TUDCA reduced
Aβ induced apoptosis of primary rat cortical neurons that was
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TABLE 2 | Genomic and metabolomics data implicating bile acids in neurodegenerative disorders.
Disease Approach Genetic association References
PD Meta-analysis of GWAS data from PD and normal patients HSD3B7 missense SNP in HSD3B7, Cheng et al., 2003; Song
and Lee, 2013
PD Meta-analysis of PD miRNA GWAS data SNPs in a miRNA-binding site in the 3’ UTR of HSD3B7 Ghanbari et al., 2016
ALS Peripheral blood cell eQTL of ALS and normal patients CYP27A1 eQTL Diekstra et al., 2012
AD Plasma metabolomic analysis of AD and normal patients Increased plasma GUDCA levels in patients with mild
cognitive impairment or AD
Mapstone et al., 2014
FIGURE 1 | Despite documented neuroprotective roles in models of
neurodegenerative disorders, the primary signaling pathways (TGR5
and FXR) and the potential role of endogenous bile acids have not yet
been studied.
found to be dependent upon the mineralocorticoid but not the
glucocorticoid receptor (Sola et al., 2006). TUDCA appeared to
interact with the ligand binding domain of the mineralocorticoid
receptor to prevent its binding to heat shock protein 90 and
subsequent trafficking for proteosomal processing allowing for
translocation to the nucleus.
Bile acids have also been studied in animal models of AD. In
double transgenic mice (APP/PS1) that express human amyloid
precursor protein carrying the KM670/671NL Swedish double
mutation and the human presenilin 1 L166P mutation under the
regulation of a neuron-specific promoter, treatment via dietary
supplementation of standard laboratory chow with 0.4% (wt/wt)
of TUDCA significantly reduced amyloid plaque number in the
frontal cortex and hippocampus, decreased injury to neurons
measured by determining loss of, or damage to, neuronal fibers
surrounding plaques, and improvedmemory retentionmeasured
via contextual, though not auditory, fear conditioning (Nunes
et al., 2012) as well as reduced hippocampal and prefrontal
amyloid deposition (Lo et al., 2013). TUDCA has also been
shown to help preserve the postsynaptic marker postsynaptic
density-95 in the hippocampus of APP/PS1 mice (Ramalho
et al., 2013). Repurposed RXR agonists or “rexinoids” have
also shown some effectiveness in transgenic models of AD
(Koster et al., 2016), suggesting a possible involvement of bile
acids.
In humans, a recent study of cognitively intact patients
identified and validated a set of blood-based biomarkers that
included glycoursodeoxycholic acid (GUDCA) that could predict
the onset of either AD or amnestic mild cognitive impairment,
considered an early precursor of AD, within 2–3 years with an
accuracy of over 90% (Mapstone et al., 2014). This suggests a
potential association of bile acids in the progression or preclinical
neurodegenerative phase of AD.
PARKINSON’S DISEASE
The effects of bile acids on chemical and genetic models of
Parkinson’s disease (PD), which is characterized by the selective
loss of dopaminergic neurons in the substantia nigra region
of the brain and a resulting tremor, have been reported.
Sodium nitroprusside (SNP)-induced cytotoxicity of human
dopaminergic SH-SY5Y cells has been used as a model of PD.
UDCA was found to dose-dependently (50–200 µM) decrease
SNP-related cell death. UDCA reduced reactive oxygen species
(ROS), reactive nitrogen species (peroxynitrite and nitric oxide),
and helped to maintain intracellular glutathione (GSH) levels.
Apoptosis markers including nuclear fragmentation, caspase
activation, and cytochrome c release were correspondingly
reduced. Inhibiting phosphatidylinositiol-3-kinase (PI3K) and
Akt/PKB blocked the favorable effects of UDCA on SNP-induced
cytotoxic cell death (Chun and Low, 2012).
Bile acids have also been implicated in PD through
genetic association studies. In a meta-analysis of genome-wide
association study (GWAS) data based on the genotypes of
2,525,705 SNPs in 4238 PD cases and 4239 non-PD controls,
a total of 3 SNPs were found to be statistically associated with
PD, including a non-synonymous missense variant in HSD3B7
(hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid
delta-isomerase 7) (Song and Lee, 2013). Recessive mutations in
HSD3B7, which catalyzes the second step in the classical pathway
of bile acid synthesis, are associated with loss of bile acid synthetic
capability and progressive liver disease (Cheng et al., 2003). In a
GWAS of 48,844 SNPs residing in miRNA-binding site variants,
32 SNPs were associated with PD that were located in the 3′
untranslated regions of 13 genes including HSD3B7 (Ghanbari
et al., 2016), providing further genetic evidence for a role of bile
acids in PD.
Mitochondrial dysfunction has been associated with
PD (Luo et al., 2015). To identify compounds that could
restore mitochondrial function in skin fibroblasts obtained
from patients with a PD parkin (PARK2) gene mutation,
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a 2000 compound library was screened for significant
improvement in mitochondrial membrane potential (Mortiboys
et al., 2013). Ursocholanic acid and the related compound
dehydro(11,12)ursolic acid lactone were among the top 15
compounds that had dose response characteristics favorable for
drug development and lacked many of the disadvantages of the
other top hits. The structurally related bile acid UDCA was also
found to rescue mitochondrial function to a similar extent, which
was dependent upon activation of the glucocorticoid receptor
and increased phosphorylation of Akt. UDCA was also found to
restore mitochondrial function in fibroblasts obtained from a PD
patient with a LRRK2-G2019S mutation.
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
neurotoxin is a widely used toxin model for PD, replicating
most of the clinical and pathological features of PD in humans
and animal models. TUDCA was found to play a role in
ameliorating neurodegeneration in MPTP-induced degeneration
of dopaminergic neurons in the nigrostriatal axis in C57BL/6
glutathione S-transferase pi (GSTP) null mice (Castro-Caldas
et al., 2012). Treatment of mice with TUDCA prior to MPTP
caused a 30% reduction in loss of dopaminergic neurons and
reduced dopaminergic fiber loss. MPTP toxicity has also been
associated with increased ROS production and activation of JNK-
mediated apoptosis (Huang et al., 2016). TUDCA reduced levels
of ROS and preserved levels of phosphorylated JNK (p-JNK)
(Castro-Caldas et al., 2012).
AMYOTROPHIC LATERAL SCLEROSIS
The loss of motor neurons in Amyotrophic lateral sclerosis
(ALS) has prompted therapeutic strategies aimed at preventing
neuronal cell death and promoting regeneration (Carvalho et al.,
2015). NSC-34 cells, created by fusion of cultured neuroblastoma
cells and motor neurons from mouse spinal cord, can be treated
with retinoic acid to induce neurite outgrowth and functional
characteristics of motor neurons and are considered a highly
stable and widely used murine motor neuron cell line model
(Maier et al., 2013; Veyrat-Durebex et al., 2014). NSC-34 cells
modified to carry the human form of SOD1 with the G93A
mutation (hSOD1G93A) have thus been used as a model for
ALS. GUDCA was reported to reduce cell death in the NSC-34
hSOD1G93A cell model and to block caspase-9 activation (Vaz
et al., 2015).
Bile acids also appear to have physiological roles in the central
nervous system. CA, a bile acid present in the adult brain,
was identified by LC/MS as a ligand of liver X receptor (LXR),
activating LXR but not FXR in ventral midbrain dopaminergic
neurons (Theofilopoulos et al., 2013). 6α-hydroxylated bile acids
and the synthetic bile acid ligand GW3965 were also highly
potent activators of LXR. Male LXR knockout mice develop an
adult-onset motor neuron degeneration that is associated with
impairment of motor coordination, axonal atrophy, astrogliosis,
accumulation of lipid and loss of motor neurons in the spinal
cord, findings similar to the neuropathology of ALS (Andersson
et al., 2005). Additionally, FXR has been shown to contribute to
normal motor function in mice (Huang et al., 2015).
Several clinical trials of bile acids have been conducted in ALS
patients in which evidence for safety and potential efficacy was
observed (Parry et al., 2010; Min et al., 2012; Elia et al., 2016). In
an ALS clinical trial with orally administered UDCA, the bile acid
was found to be well tolerated and crossed into the cerebrospinal
fluid in a dose-dependent manner (Parry et al., 2010). In a
separate clinical trial to test the efficacy of UDCA for treating
ALS patients, oral solubilized administration for 3 months was
shown to be well tolerated and there was a slight decrease in the
progression of ALS in the treatment group as compared to the
placebo group (Min et al., 2012). However, due to the small size of
the study and the high rate of patient dropout, the efficacy of the
treatment was inconclusive. TUDCA administered orally twice
per day for over 1 year resulted in a higher percentage of subjects
achieving at least a 15% improvement in the ALS Functional
Rating Scale Revised (ALSFRS-R) slope (Elia et al., 2016).
Genetic data also implicates bile acid metabolism in ALS.
Gene expression profiles obtained from the peripheral blood cells
of sporadic ALS patients and normal controls were analyzed
in the context of genome-wide SNP genotype data to identify
expression quantitative trait loci (eQTLs). A cluster of transcript-
SNP pairs with the highest level of statistical significance and
meeting correction for multiple testing was associated with
CYP27A1 expression in ALS (Diekstra et al., 2012). CYP27A1
is a key enzyme in the alternative bile acid synthesis pathway,
and mutations in this enzyme can cause cerebrotendinous
xanthomatosis as described below.
HUNTINGTON’S DISEASE
Huntington’s disease (HD), an autosomal dominantly inherited
neurodegenerative disease, is caused by an expansion mutation
in CAG triplet repeat number in exon 1 of the huntingtin
(HTT) gene (Ross et al., 2014). It is characterized by involuntary
choreic movements, psychiatric and behavioral disturbances, and
impaired cognitive function. Genetic and chemical animal and
cellular models have been developed in which the effects of bile
acids have been assessed. For example, 3-nitropropionic acid,
an irreversible chemical inhibitor of mitochondrial succinate
dehydrogenase, can be used to induce apoptosis of cells in
culture and in neurons in the striatum region of the brain that
causes changes similar to the morphology and neurochemical
changes of HD. Incubation of rat neuronal RN33B cells with
TUDCA was found to reduce 3-nitropropionic acid induced
apoptosis by about 80% (Rodrigues et al., 2000). Other bile
acids, including UDCA and GUDCA, were also associated
with decreased apoptosis, preventing 3-nitropropionic acid
induced release of mitochondrial cytochrome c, and associated
morphological changes in both isolated mitochondria and in
intact cells. In rats treated with TUDCA, a similar level of
reduction in apoptosis and in the volume of lesions associated
with administration of 3-nitropropionic acid was observed that
was correlated with preservation of sensorimotor function and
performance in cognitive task assays (Keene et al., 2001). These
results suggest that the mechanisms of bile acid protection may
be similar both in vitro and in vivo.
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Genetic models of HD have also been studied, including
the R6/2 mouse, which is transgenic for a 150 repeat
trinucleotide CAG expansion in exon 1 of HTT and manifests
severe neurodegeneration, neuronal intranuclear inclusions,
and sensorimotor deficits that result in a severely shortened
survival of less than 4 months of age (Mangiarini et al., 1996;
Davies et al., 1997). TUDCA treatment was administered to
the R6/2 transgenic mice subcutaneously at a dose of 500
mg/kg once every 3 days from weaning to 6 months of age,
which was tolerated without skin reaction or other effects. The
subcutaneously administered TUDCA was absorbed into the
circulation, crossed the blood-brain barrier, and produced seven-
fold increases in UDCA levels in the brain without evidence
of adverse effects. TUDCA treatment resulted in significantly
reduced striatal cell apoptosis, decreased levels of intracellular
inclusions, and improved locomotor open field and sensorimotor
Rota-Rod performances (Keene et al., 2002).
SPINOCEREBELLAR ATAXIA TYPE 1
Spinocerebellar ataxia type 1 (SCA1) is another dominantly
inherited neurodegenerative disorder characterized chiefly by
progressive ataxia (Meera et al., 2016). SCA1 is caused by
expansion of an unstable CAG trinucleotide repeat that encodes
a glutamine tract in the Ataxin-1 gene (ATXN1). The disorder
is characterized primarily by degeneration of Purkinje neurons
of the cerebellum. TUDCA treatment was used to determine
whether the survival of Purkinje cells and the onset and
progression of ataxia was altered in a transgenic mouse model of
SCA1, in which 30 copies of the humanATXN1 cDNA containing
a CAG trinucleotide repeat of 82 repeats was under the control
of the Pcp-2 Purkinje-cell specific promoter l (Kaemmerer et al.,
2001). Despite the successful administration of TUDCA using
a similar subcutaneous injection protocol as described above
for the R6/2 transgenic HD mouse, and documentation of
increased levels in the brain, no effects on cell survival or on the
neurological phenotype were noted. The disparate effects in two
different genetic models of neurodegenerative disease, suggest
that bile acids target specific pathways.
PRION DISEASES
Neurodegenerative disorders caused by prions include
Creutzfeldt-Jakob disease and similar disorders in animals such
as bovine spongiform encephalopathy in cows, chronic wasting
disease in deer, and scrapie in sheep (Imran andMahmood, 2011;
Windl and Dawson, 2012). Prion protein (PrPC) is a normal
cellular protein that when mutated becomes misfolded (PrPSc).
PrPSc can then convert normally folded PrPC to the misfolded
form. Accumulation of PrPSc causes loss of neurons, astrogliosis,
and spongiform degeneration resulting in dementia, ataxia, and
death. One approach to therapeutic development has been to
block or interfere with the conversion of PrPC to PrPSc. TUDCA
and UDCA were found to substantially reduce this conversion
in cell-free aggregation assays as well as in both chronically and
acutely infected mouse ScN2a neuroblastoma cells (Cortez et al.,
2015). TUDCA and UDCA also reduced neuronal loss in a prion
organotypic slice culture model of intracerebral infection that
assesses prion replication occurring ex vivo through infection
of brain slices with prion infected brain homogenate. UDCA
treatment also reduced astrocytosis and prolonged survival
in prion infected male C57BL/6 mice, although whether bile
acids interacted with the PrPC to PrPSc conversion or mediated
protective effects through some other mechanism is not
known.
CEREBROTENDINOUS XANTHOMATOSIS
Cerebrotendinous xanthomatosis (CTX) is a very rare autosomal
recessive disorder caused by mutations in the CYP27A1
gene (Björkhem and Hansson, 2010; Bjorkhem, 2013). These
mutations lead to deficiency of the sterol 27-hydroxylase inner
mitochondrial membrane protein. Sterol 27-hydroxylase oxidizes
cholesterol to 27-hydroxycholesterol in the alternative bile acid
synthesis pathway that leads to the generation of CDCA. Sterol
27-hydroxylase deficiency leads to a reduction of CDCA and
upregulation of cholesterol 7α-hydroxylase (CYP7A1), the rate-
limiting enzyme in the classic bile acid synthesis pathway
resulting in elevated levels of cholestanol and bile alcohols. CTX
patients have a mean age of diagnosis of 35 years and manifest
multiple neurologic symptoms including dementia, ataxia,
peripheral neuropathy, epilepsy, myopathy, and psychiatric
disorders, as well as a variety of non-neurological manifestations
including premature atherosclerosis, tendon xanthomas, juvenile
onset cataracts, osteoporosis, and mild pulmonary insufficiency.
Long-term treatment with CDCA can result in amelioration of
neurological symptoms and an improved prognosis.
RETINAL DISEASES
Bear bile has been used in Chinese medicine for several millennia
to treat visual disorders (Boatright et al., 2006). This has led
to a number of studies investigating the primary constituent of
bear bile, TUDCA, as a potential therapeutic agent for several
ophthalmological diseases (Boatright et al., 2009). TUDCA
has been investigated in retinitis pigmentosa, a heterogeneous
group of disorders of retinal degeneration in which progressive
peripheral and night vision loss occurs, with central vision
impairment. Mutations in about 200 genes, including the gene
encoding rhodopsin (RHO), have been identified that cause
apoptosis of photoreceptor cells (Daiger et al., 2013). The RHO
P23Hmutation is themost common cause of retinitis pigmentosa
in the United States that is thought to produce structurally
altered folding with retention in the endoplasmic reticulum and
resulting cytotoxicity. TUDCA administered intraperitoneally
once a week from weaning until 4 months of age to homozygous
P23H line-3 rats reduced photoreceptor loss across the retina
and preserved synapses between photoreceptors and bipolar or
horizontal cells (Fernandez-Sanchez et al., 2011). In the rd10
mouse model of retinitis pigmentosa, in which the mice carry
a missense mutation in exon 7 of the Pde6b gene resulting
in rod photoreceptor cell death within a month after birth,
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subcutaneous administration of TUDCA resulted in higher cone
cell density in all 4 quadrants of the retina (Oveson et al., 2011).
TUDCA also decreased apoptosis, preserved the normal retinal
photoreceptor cellular architecture, and maintained amplitudes
of dark-adapted electroretinogram a- and b-waves (Boatright
et al., 2006), even at later stages of severe photoreceptor loss
(Phillips et al., 2008).
Mutations in the retinoid isomerase (RPE65) or lecithin-
retinol acyltransferase (LRAT) genes underlie Leber congenital
amaurosis (den Hollander et al., 2008). LRAT is involved in 11-
cis retinal recycling in the retinal pigment epithelium through
mediating the esterification of all-trans retinol to all-trans retinyl
esters, which are the substrates for RPE65. Homozygous Lrat
knockout mice that were subcutaneously administered TUDCA
every 3 days from 1 to 4 weeks after birth had about a three-
fold increase in cone density in the ventral and central retina
and increased ER-associated protein degradation (Zhang et al.,
2012; Fu and Zhang, 2014). Twice per week subcutaneous
injections of TUDCA also preserved ERG b-waves and the outer
nuclear layer of the retina in Bardet-Biedl syndrome type 1
mice (Bbs1M390R/M390R), another model for retinal degeneration
(Drack et al., 2012).
TUDCA ameliorated cell death and loss of photoreceptor
function after exposure to high levels of light (10,000 lux) that
can induce retinal degeneration in albino Balb/C mice (Boatright
et al., 2006). TUDCA pre-treatment of ex vivo perfused whole
mount feline retinas repeatedly exposed to light stimulation
and dark adaptations over 5 h resulted in greater receptive
field size, decreased irradiance threshold, and maintenance of
the contrast threshold (Xia et al., 2015). Retinal dystrophy can
be caused by defects in the phagocytosis by retinal pigment
epithelium cells of the photoreceptor outer segments that are
shed, a continuous and extremely active process involving
thousands of shed membranous disks each day. TUDCA was
found to increase phagocytic activity and inhibit hydrogen
peroxide induced impairment of phagocytosis by both cultured
ARPE-19 cells and primary human retinal pigment epithelium
cells (Murase et al., 2015). The phosphorylation of MerTK was
significantly increased by TUDCA in a concentration-dependent
manner but did not affect expression of the ER stress marker
glucose regulated protein-78 (GRP-78).
Bile acids also had an effect in ameliorating cell death in
a model of retinal detachment via intraperitoneal injection of
TUDCA at 3 and 5 days post detachment, times when acute
photoreceptor loss occurs in the outer nuclear layer of the retina
(Mantopoulos et al., 2011). TUDCA treatment also blocked
the production of protein carbonyls with decreased caspase
activation but did not decrease endoplasmic reticulum (ER)
stress. In a diabetic retinopathy model, TUDCA significantly
decreased apoptosis measured by TUNEL assay of primary rat
retinal neural cells exposed to 30 mM glucose concentration,
which causes caspase-independent cell death (Gaspar et al.,
2013). TUDCA also decreased the amount of apoptosis-inducing
factor (AIF) released from the mitochondria and its subsequent
accumulation in the nucleus. Production of protein carbonyls
and ROS were also significantly decreased after TUDCA
treatment.
Over-stimulation of N-methyl-D-aspartate (NMDA)
receptors, one of three ionotropic glutamate receptor subtypes
that are expressed in inner retinal cells, by intravitreal injection
of NMDA has frequently been used to model the cell death
pathway that occurs in retinal diseases such as glaucoma
(Danesh-Meyer, 2011). This model of excitotoxicity causes
disruption of sodium-potassium balance, calcium overload,
mitochondrial dysfunction, and oxidative stress (Gomez-Vicente
et al., 2015). In mice, administration of TUDCA prior to the
intravitreal injection of NMDA was found to increase survival of
retinal ganglion cells.
ACUTE STROKE, SPINAL CORD INJURY,
AND NEUROPATHY
A single intravenous (i.v.) dose of TUDCA administered to rats
60 min after occlusion of the middle cerebral artery markedly
reduced infarct size and apoptosis and preserved mitochondrial
integrity (Rodrigues et al., 2002). The single i.v. dose resulted in a
significant increase in brain UDCA levels from near undetectable
levels to 0.15 nmol/g. TUDCA was also found to have an anti-
inflammatory effect in the context of the central nervous system.
TUDCA reduced glial cell activation and microglial chemotaxis
and reduced expression of the MCP-1 chemoattractant and
vascular adhesion proteins such as VCAM-1 in microglial cells
and astrocytes treated with either interferon gamma (IFN-γ)
or lipopolysaccharide and IFN-γ (Yanguas-Casás et al., 2014).
Injection of TUDCA into the carotid artery 1 h prior to or up
to 6 h after collagenase injection into the striatum to induce
hemorrhagic lesions decreased lesion volumes, peri-hematoma
apoptosis, and caspase activity at 2 days by about 50%, as well
as decreased NF-κB and increased AKT activation that was
associated with neurobehavioral improvement (Rodrigues et al.,
2003). TUDCA injected intraperitoneally 1 min after spinal cord
crush injury decreased apoptosis and corresponding tissue injury
(Colak et al., 2008). In a phase II open-label study of oral
doxycycline and TUDCA taken three times/day for 1 year in
patients with transthyretin amyloidosis (ATTR), progression of
neuropathy was stabilized (Obici et al., 2012).
MODULATION OF NEUROTRANSMITTER
ACTIVITY
The wake period of normal mice was found to be increased with
administration of UDCA that also decreased slow wave sleep
(Yanovsky et al., 2012). In contrast, administration of UDCA
to histidine decarboxylase knockout mice, that are deficient
in histamine that stimulates arousal, decreased wakefulness
and altered cortical EEG and sleep-wake parameters. Using
in vitro patch-clamp recordings from histaminergic neurons,
UDCA was found to inhibit GABAergic currents and to serve
as an antagonist for GABAA receptors expressed in HEK293
cells. In one of the few studies to analyze more than one or
two bile acids, a structure-function relationship analysis was
performed using cultured hypothalamic neurons (Schubring
et al., 2012). Bile acids were found to modulate firing frequency
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and synchrony, and to block activity of GABAA and NMDA
receptors. Antagonist activity for both the GABAA and NMDA
receptors was strongest for CDCA followed by DCA, CA, and
dehydrocholate. Involvement of bile acid binding to TGR5 was
excluded as a potential mechanism in the neurotransmitter
receptor blockade (Keitel et al., 2010).
CAwas found to serve as an inhibiter for N-type Ca2+ channel
currents of neurons isolated from the caudal paravertebral
sympathetic ganglia of adult bull frogs (Rana catesbeiana),
although open and shut times, slope conductance, and single
channel current amplitude, were not significantly affected (Lee
et al., 2012). Overstimulation of glutamate receptors to induce
excitotoxicity in neurons isolated from late stage fetal rat
brains was largely suppressed by GUDCA. This bile acid
appeared to suppress glutamate release in either normal or
microglia-depleted hippocampal tissue slices (Silva et al., 2012).
Pretreatment of primary cultures of fetal rat cortical neurons with
TUDCA significantly reduced glutamate excitotoxicity associated
cell death. TUDCA treatment resulted in phosphorylation
and translocation of the pro-apoptotic Bad protein from the
mitochondria to the cytosol. Inhibiting the PI3K signaling
pathway blocked the anti-apoptotic effects of TUDCA (Castro
et al., 2004).
POTENTIAL AS NEUROTROPHIC
FACTORS
Neurotrophic factors are classified primarily as proteins that
bind to receptors, e.g., tropomyosin related kinase receptors
TrkA, TrkB, and TrkC and p75 neurotrophin receptor (p75NTR)
that can modulate Trk activation, to activate signaling pathways
that promote neuronal growth and survival (Rodrigues et al.,
2014). Several molecules have been identified as neurotrophic
factors, including brain-derived neurotrophic factor (BDNF),
ciliary neurotrophic factor (CNTF), and glial cell-line-derived
neurotrophic factor (GDNF) that can stimulate the growth
and differentiation of neuronal cells, as well as prevent cell
death. Despite the therapeutic promise of such neurotrophic
factors for treating neurodegenerative disorders (Tovar-Y-Romo
et al., 2014), their limited bioavailability presents a major
roadblock. Mimetics with more favorable bioavailability profiles
FIGURE 2 | Molecular pathways implicated in the neuroprotective effects of bile acids in neurodegenerative disease models. Despite the relatively large
structurally related group of bile acids, relatively few have been studied in neurodegenerative disorders. A major focus has been on apoptotic pathways and the PI3
kinase and AKT signaling pathway. Surprisingly, the primary signaling pathways through which bile acids act, TGR5, FXR, and FXR/RXR have received essentially no
attention (designated by “?”), despite that retinoic acid is known to be a potent neurotrophic molecule.
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have therefore been pursued (Tiwari and Chaturvedi, 2014),
as well as investigation of proneurogenic peptides and small
molecules that exhibit neuroprotective properties (Airavaara
et al., 2012), including retinoic acid (Malik et al., 2000; Riancho
et al., 2016). Retinoic acid shares a common role in regulating
lipid homeostasis with bile acids, whose cognate receptor FXR
can form heterodimers with RXRα. Thus, retinoic acid may
activate the FXR signaling pathway and vice versa (Yang et al.,
2014). Whether bile acids mediate effects in the nervous system
through a similar mechanism is not known (Figure 1).
CONCLUSIONS AND OUTLOOK
Neuroprotective effects of several bile acids are well documented
in a wide range of neurodegenerative diseases, including AD, PD,
ALS, HD, and retinal degeneration, in cellular and animal models
and in human clinical trials. Due to the historical precedent
set by the use of bear bile in ancient Chinese medicine, the
majority of the studies have focused onUDCA and its derivatives.
However, bile acids are a relatively large group of structurally
related molecules, thus little is known about the potential
efficacy of other bile acid species or the roles of circulating vs.
endogenous bile acids synthesized within the central nervous
system. In addition, most of the mechanistic studies have
been centered on apoptosis and related pathways (Figure 2).
However, essentially no data is available on the primary signaling
pathways through which bile acids act, the cellular receptor
TGR5 and the nuclear receptors FXR and RXRα, despite the
well-known function of retinoic acid as a potent neurotrophic
molecule. Determining the precise molecular mechanism(s) of
neuroprotection by bile acids in neurodegenerative disorders will
be important to realize their future therapeutic potential.
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